Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Philips NV
  6. News
  7. Summary
    PHIA   NL0000009538


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca raises sales forecast after second quarter cancer drug, China boost

07/25/2019 | 10:42am EDT
The logo of AstraZeneca is seen on a medication package in a pharmacy in London

(Reuters) - AstraZeneca Plc raised its product sales forecast for 2019 on Thursday after second-quarter results beat analysts' expectations, thanks to strong sales from cancer medicines and emerging markets, especially China.

The British drugmaker's shares rose more than 8% to hit a record high of 6,581 pence by 1423 GMT, bringing gains for the year so far to nearly 17% as Chief Executive Officer Pascal Soriot's turnaround plan gained traction.

AstraZeneca, which maintained its dividend, reported a rise in drug sales for the fourth consecutive quarter after posting years of decline in sales due to patent losses on older drugs.

"The momentum generated last year continued into the first half, consolidating AstraZeneca's return to growth based on the strength of our new medicines," Soriot said. "We are very optimistic for the next few quarters."

Sales from its oncology unit soared 57% to $2.17 billion (£1.74 billion), accounting for 38% of total product sales, with revenue from the company's top-seller - lung cancer drug Tagrisso - nearly doubling to $784 million.

"We appear to be in the middle of a positive run for the near term. This is likely to be the case for the short to medium term," David Madden, a market analyst at CMC Markets told Reuters, but added the market would be looking at what was next in the pipeline.

"You can't be dining out on the success of one cancer drug forever."

The company has moved deeper into cancer therapy through wide-ranging deals, including those for immunotherapy and targeted therapy. Earlier this year, it agreed a multi-billion dollar oncology deal with Japan's Daiichi Sankyo Co.

AstraZeneca's focus on China has also resulted in explosive growth, with sales more than doubling since 2012 on the back of partnerships with local players and a softening of the regulatory environment for pharmaceutical firms.

Chinese sales rose 44% in the three-month period to $1.17 billion, accounting for more than half of its sales in the developing world.

(For a graphic on 'Oncology and China sales boost AstraZeneca', click

(For an
interactive graphic on AstraZeneca's oncology and China growth, click herehttps://tmsnrt.rs/2y80M5t

The drugmaker, however, has warned that growth may not be sustainable.

"We are very pleased with overall performance of China," Ruud Dobber, executive vice president, BioPharma, told Reuters, but added the company still expected changing policies in the country to hurt sales of its cholesterol drug, Crestor.

China has been a bright spot for other companies, including Swiss drugmaker Roche and Dutch health technology company Philips, which posted better-than-expected quarterly sales growth earlier this week due to rising healthcare spending by the Chinese government.

AstraZeneca said it now expects full-year product sales to increase by a low double-digit percentage, compared to a previous forecast of high single-digit percentage growth but it maintained its forecast for 2019 core earnings.

Quarterly sales rose 19% to $5.72 billion at constant currency, above analysts' consensus of $5.45 billion.

Core earnings were 73 cents per share, beating analysts' average expectation of 61 cents per share, according to a company provided consensus.

Like other players, AstraZeneca has been one of the focal points for concern over supplies of drugs if Britain leaves the European Union without a withdrawal deal later this year.

The company reiterated on Thursday that it was prepared for the breakup, even if it was a no-deal exit.

"We are as ready as we can be," Soriot added.

(Reporting by Pushkala Aripaka and Ankur Banerjee in Bengaluru; Editing by Patrick Graham and David Evans)

By Pushkala Aripaka and Ankur Banerjee

ę Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.08% 8996 Delayed Quote.22.80%
DAIICHI SANKYO COMPANY, LIMITED 1.02% 2884 End-of-day quote.-18.42%
EURO / US DOLLAR (EUR/USD) -0.02% 1.15975 Delayed Quote.-5.06%
NEXT PLC -0.77% 7946 Delayed Quote.12.16%
PHILIPS NV -1.29% 40.64 Real-time Quote.-7.17%
ROCHE HOLDING AG -0.95% 354.55 Delayed Quote.15.84%
SWISS RE LTD 1.24% 85.02 Delayed Quote.0.77%
All news about PHILIPS NV
12:08pPhilips Spectral CT 7500 receives Minnie Award for Best New Radiology Device
07:56aPHILIPS NV : Gets a Buy rating from Barclays
06:12aUnilever, 39 Others Win Permit to Establish Regional Headquarters in Saudi Arabia
10/25PHILIPS : Credit Suisse Cuts Price Target on Philips to EUR42 From EUR49, Citing 'De-Ratin..
10/25PHILIPS : brings clarity to every moment of cancer care with new patient-centered innovati..
10/25PHILIPS NV : Credit Suisse reaffirms its Neutral rating
10/21PHILIPS : brings clarity to every moment of cancer care with new patient-centered innovati..
10/21Royal Philips Announces New Innovations to Help Improve Cancer Care Across Patient Jour..
10/21PHILIPS : Seeing the bigger picture … and taking action together!
10/21PHILIPS : "Al bij de eerste design-schets moet je nadenken over circulariteit"
More news
Analyst Recommendations on PHILIPS NV
More recommendations
Sales 2021 17 543 M 20 335 M 20 335 M
Net income 2021 3 577 M 4 147 M 4 147 M
Net Debt 2021 4 001 M 4 638 M 4 638 M
P/E ratio 2021 9,26x
Yield 2021 2,22%
Capitalization 36 995 M 42 873 M 42 883 M
EV / Sales 2021 2,34x
EV / Sales 2022 2,18x
Nbr of Employees 77 084
Free-Float 99,4%
Duration : Period :
Philips NV Technical Analysis Chart | PHIA | NL0000009538 | MarketScreener
Technical analysis trends PHILIPS NV
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 40,64 €
Average target price 46,21 €
Spread / Average Target 13,7%
EPS Revisions
Managers and Directors
Frans van Houten Chief Executive Officer
Abhijit Bhattacharya Chief Financial Officer & Executive Vice President
Feike Sijbesma Chairman-Supervisory Board
Jan Kimpen Chief Medical Officer
Sophie Bechu Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
PHILIPS NV-7.17%43 452